Loading...
Market
Will FDA approve Eftilagimod Alpha and Pembrolizumab for PD-L1-negative HNSCC by December 31, 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and official press releases
Story
Immutep Reports Positive Results in PD-L1-Negative Head and Neck Cancer with Eftilagimod Alpha and Pembrolizumab
Jul 12, 2024, 01:54 PM
Immutep has reported positive results in first-line treatment of head and neck squamous cell carcinoma (HNSCC) patients with negative PD-L1 expression. The results were achieved using a combination of Eftilagimod Alpha and Pembrolizumab, which generated a favorable overall response rate (ORR). This announcement has led to an 18.4% pre-market increase in Immutep's stock price ($IMMP). The findings were highlighted during the ESMO Virtual Plenary and have been met with significant interest in the oncology community. The results were reported by SI.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%